« Previous
Next »
Titles
- IRB waiver or alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects: guidance for sponsors, investigators, and institutional review boards1
- Impact of cost sharing reductions on deductibles and out-of-pocket limits1
- Implantable devices: regulatory framework and reform options1
- Implications of navigator funding changes on people with HIV: navigator perspectives1
- Implications of reduced federal Medicaid funds: how could states fill the funding gap?1
- Imported seafood safety: FDA and USDA could strengthen efforts to prevent unsafe drug residues : report to the chairman, Committee on Appropriations, U.S. Senate1
- Improper payments: improvements needed in CMS and IRS controls over health insurance premium tax credit : report to Congressional committees1
- Income and assets of Medicare beneficiaries, 2016--20351
- Individual insurance market performance in mid 20171
- Intensive outpatient care program: a care model for the medically complex piloted by employers1
- Investigational new drugs: FDA has taken steps to improve the expanded access program but should further clarify how adverse events data are used : report to Congressional addressees1
- Investigational new drugs: FDA's expanded access program : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Is working longer a good prescription for all?1
- Issues and challenges in measuring and improving the quality of health care1